In March, comparing the price of a cancer drug on a per capita basis here and in India, I told drug companies how to charge $1.6 million per patient for a new drug — and get away with it. So long as companies make sure that all patients have access, I argued, it’s possible to convince governments and insurers to pay truly princely sums for medicines that really help patients.
Still, I thought that $1.6 million, was a sky high, off-the-charts, unbelievable amount. Surely, no medicine for sale today cost more than $1 million I thought. In fact, the priciest one I can name is Soliris, from biotech high-flyer Alexion, which costs $500,000 per patient — a lot, but still only half a million. Turns out I was wrong — it’s possible that medicines that are already on the market could rise to this price point, if they continue to help young patients grow bigger.
Read the full story: http://hcp.lv/Jnp488
Source: Forbes
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
January 28th 2023The FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a previous Bruton tyrosine kinase (BTK) inhibitor.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Female Adolescents With T1D Have Lower Quality of Life Than Male Children
January 27th 2023A systematic review evaluating sex differences in children with type 1 diabetes (T1D) found that female children had higher rates of comorbidities, higher body mass index, required higher insulin doses, and had a lower quality of life compared with male children.
Read More
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
2 Clarke Drive
Cranbury, NJ 08512